Skip to content
  • Submit

  • Category

  • Sort by

  • Per page

Found 9972 publications. Showing page 269 of 399:

Publication  
Year  
Category

Episodes of cross-polar transport in the Arctic troposphere during July 2008 as seen from models, satellite, and aircraft observations.

Sodemann, H.; Pommier, M.; Arnold, S.R.; Monks, S.A.; Stebel, K.; Burkhart, J.F.; Hair, J.W.; Diskin, G.S.; Clerbaux, C.; Coheur, P.-F.; Hurtmans, D.; Schlager, H.; Blechschmidt, A.-M.; Kristjánsson, J.E.; Stohl, A.

2011

Episodes of cross-polar transport in the Arctic during July 2008 as seen from models and observations. Poster presentation. NILU F

Sodemann, H.; Pommier, M.; Monks, S.; Arnold, S.; Stebel, K.; Burkhart, J.

2010

Epigenetics in breast cancer therapy—New strategies and future nanomedicine perspectives

Epigenetic dysregulation has been recognized as a critical factor contributing to the development of resistance against standard chemotherapy and to breast cancer progression via epithelial-to-mesenchymal transition. Although the efficacy of the first-generation epigenetic drugs (epi-drugs) in solid tumor management has been disappointing, there is an increasing body of evidence showing that epigenome modulation, in synergy with other therapeutic approaches, could play an important role in cancer treatment, reversing acquired therapy resistance. However, the epigenetic therapy of solid malignancies is not straightforward. The emergence of nanotechnologies applied to medicine has brought new opportunities to advance the targeted delivery of epi-drugs while improving their stability and solubility, and minimizing off-target effects. Furthermore, the omics technologies, as powerful molecular epidemiology screening tools, enable new diagnostic and prognostic epigenetic biomarker identification, allowing for patient stratification and tailored management. In combination with new-generation epi-drugs, nanomedicine can help to overcome low therapeutic efficacy in treatment-resistant tumors. This review provides an overview of ongoing clinical trials focusing on combination therapies employing epi-drugs for breast cancer treatment and summarizes the latest nano-based targeted delivery approaches for epi-drugs. Moreover, it highlights the current limitations and obstacles associated with applying these experimental strategies in the clinics.

2020

Epigenetic effects of nanomaterials

Smolkova, Bozena; Dusinska, Maria; Gábelová, Alena

2019

Epigenetic changes induced by nanomaterials and possible impact on health.

Smolková, B.; Gábelová, A.; Šrámková, M.; Kozics, K.; Sran¿íková, A. M.; Dusinska, M.

2017

EO-based Downscaling for Urban-Scale Air Quality Applications

Schneider, Philipp; Shetty, Shobitha; Hamer, Paul David; Stebel, Kerstin; Kylling, Arve; Hassani, Amirhossein; Berntsen, Terje Koren; Grythe, Henrik; Lopez-Aparicio, Susana; Vallejo, Islen; Weydahl, Torleif; Markelj, Miha

2025

Environmental toxins and you.

Hanssen, L.; Nøst, T. H.

2016

Environmental tobacco smoke exposure and children's health.

Polanska, K.; Hanke, W.; Ronchetti, R.; Van Den Hazel, P.; Zuurbier, M.; Koppe, J.; Bartonova, A.

2006

Environmental sustainability of urban expansion: Implications for transport emissions, air pollution, and city growth

Lopez-Aparicio, Susana; Grythe, Henrik; Drabicki, Arkadiusz; Chwastek, Konrad; Tobola, Kamila; Górska-Niemas, Lidia; Kierpiec, Urszula; Markelj, Miha; Strużewska, Joanna; Kud, Bartosz; Sousa Santos, Gabriela

This study examines the environmental impacts of urban growth in Warsaw since 2006 and models the implications of future urban development for traffic pollutant emissions and pollution levels. Our findings demonstrate that, over the past two decades, urban sprawl has resulted in decreases in accessibility to public transport, social services, and natural areas. We analyse CO2 traffic emissions, NO2 concentrations, and population exposure across urban areas in future scenarios of further sprawling or alternative compacting land-use development. Results indicate that a compact future scenario reduces transport CO2 emissions and urban NO2 levels, though increases in population density raise exposure to air pollution. A sprawl future scenario increases CO2 and NOx emissions due to longer commutes and congestion, and NO2 levels increase up to 25% in parts of the city. Several traffic abatement strategies were simulated, and in all simulations a compact city consistently yields the largest reductions in CO2 emissions and NO2 levels, implying that the best abatement strategy for combating negative consequences of sprawl is to reduce sprawling. In both city layouts, network-wide improvements of public transport travel times gave significantly reduced emissions. Combined, our findings highlight the importance of co-beneficial urban planning strategies to balance CO2 emissions reduction, and air pollution exposure in expanding cities.

Elsevier

2025

Environmental speed limits

Grythe, Henrik; Lopez-Aparicio, Susana

2020

Environmental solutions

Tarrasón, Leonor

2018

Environmental services and data brokerage portal: ENV-e-CITY in action.

Moussiopoulos, N.; Karatzas, K.; Endregard, G.; Fedra, K.; Friedrich, R.; Johansen, P.H.; Kalognomou, L.; Karppinen, A.; Kraggerud, P.H.; Kukkonen, J.; Larssen, S.; De Leeuw, F.; Lohmeyer, A.; Naneris, C.; Nicklass, D.; Papaioannou, G.; Peinel, G.; Pulles, T.; Reis, S.; Rose, T.; Sedlmayr, M.; van den Hout, D.

2003

Environmental screening of selected organic compounds 2008. Human and hospital-use pharmaceuticals, aquaculture medicines and personal care products. NILU OR

Schlabach, M.; Dye, C.; Kaj, L.; Klausen, S.; Langford, K.; Leknes, H.; Moe, M.K.; Remberger, M.; Schøyen, M.; Thomas, K.; Vogelsang, C.

2009

Publication
Year
Category